PharmaSeq

Home Company News & Events Press Releases 2008 PharmaSeq Receives Government Grant to Conduct Clinical Testing of Gene Assay

Press Releases

PharmaSeq Receives Government Grant to Conduct Clinical Testing of Gene Assay

Monmouth Junction, NJ, September 22, 2008. PharmaSeq, Inc., is pleased to announce the award of a large SBIR Phase II grant for a project entitled "Rapid Cystic Fibrosis Mutation Screening Test". The grant was awarded by the National Heart, Lung and Blood Institute of the NIH. Its purpose is to support a clinical study of a new in vitro diagnostic capable of detecting mutations in the gene responsible for cystic fibrosis. The diagnostic consists of a microtransponder-based, multiplex DNA assay and a bench-top analyzer.

The benefits of the program include improved detection of disease-related mutations, leading to better health care for cystic fibrosis-affected individuals, and extending clinical understanding of the genetic basis of the disease. The instrumentation and the assay platform will also be made available for a wide variety of additional genetic and proteomic-type tests.

Dr. Wlodek Mandecki, President of PharmaSeq, Inc., said: "This grant award validates the scientific community's recognition of the potential for our microtransponder technology as a powerful tool for multiplex diagnostics. The grant will allow us to complete the clinical testing of the cystic fibrosis diagnostic, and will lead to introduction of our system for clinical use."

The assay detects 50 mutations associated with cystic fibrosis and is implemented on microtransponders that are small electronic chips. Each microtransponder is composed of photocells, antenna and memory to store information that identifies the sequence of the DNA probes attached to the microtransponder's surface. In an assay, labeled target DNA binds to DNA probes and is visualized with a fluorescent staining reagent. The fluorescence intensity of the microtransponder surface is quantified in a flow-based analyzer that also determines the serial number of the microtransponder. Microtransponders and readers are all designed and built by PharmaSeq.

For further information, please contact Dr. Richard Morris, CEO, or Dr. Wlodek Mandecki, President, at (732) 355-0100 ext 11.

PharmaSeq, Inc.
11 Deer Park Drive, Suite 104
Monmouth Junction, NJ 08852
Find us on the web at: www.pharmaseq.com.

Home Company News & Events Press Releases 2008 PharmaSeq Receives Government Grant to Conduct Clinical Testing of Gene Assay